Can't be definitive without going through the actual review process.If it's denied at review for one reason or the other it can't be put back to being ill-advised.
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-19
-
- There are more pages in this discussion • 1,078 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.065(6.07%) |
Mkt cap ! $1.147B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.05 | 99.5¢ | $9.449M | 9.298M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 64999 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 64541 | 3 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |